Paul Bourgine and his group members proposed to validate the OssiGel technology in the context of Acute Myeloid Leukemia (AML). The aim was to generate personalized human ossicles from AML patients cells and test whether the patient ossicles will reflect leukemia development which is occurring in their bones. Next, they planned to validate the human ossicles as an advanced in vivo drug-testing platform, where Paul proposes to demonstrate the possibility of assessing patient-drug responses with standard-of-care treatments.

At the end of the planned project, OssiGel is expected to be validated as a superior personalized platform to predict patient's drug responses, which will lay the foundation for the development of a commercial product through the creation of a start-up company. The creation of a start-up company will start attracting venture funding and in 2024, we Paul and his team will initiate the distribution and validation of the OssiGel product to collaborators such as local academic groups and companies. Following initial distribution locally, Paul and his team expects to distribute the product more broadly in Sweden and Denmark, where an industrial partner could be identified for global production and distribution of OssiGel.